4.8 Review

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Multidisciplinary Sciences

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Jedd D. Wolchok et al.

PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 (2013)

Article Oncology

Ipilimumab and Its Toxicities: A Multidisciplinary Approach

Leslie A. Fecher et al.

ONCOLOGIST (2013)

Article Oncology

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Jeffrey S. Weber et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

News Item Biotechnology & Applied Microbiology

Anti-IL-17 mAbs herald new options in psoriasis

Ken Garber

NATURE BIOTECHNOLOGY (2012)

Article Medicine, General & Internal

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

Michael A. Postow et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Letter Oncology

Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient

S. Wilgenhof et al.

ANNALS OF ONCOLOGY (2011)

Article Endocrinology & Metabolism

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

Le Min et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)

Letter Medicine, General & Internal

Hemophilia A Induced by Ipilimumab

Julie Delyon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Article Medicine, General & Internal

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Article Immunology

Cutting Edge: CTLA-4-B7 Interaction Suppresses Th17 Cell Differentiation

Haiyan Ying et al.

JOURNAL OF IMMUNOLOGY (2010)

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Medicine, Research & Experimental

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

Erika von Euw et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2009)

Letter Medicine, General & Internal

Anti-CTLA4 Antibody-Induced Lupus Nephritis.

Fouad Fadel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Article Multidisciplinary Sciences

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

Marcella Fasso et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Article Multidisciplinary Sciences

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

Jianda Yuan et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Article Medicine, Research & Experimental

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

Sergio A. Quezada et al.

JOURNAL OF CLINICAL INVESTIGATION (2006)

Article Multidisciplinary Sciences

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

GQ Phan et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

Article Multidisciplinary Sciences

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

FS Hodi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

Article Biochemistry & Molecular Biology

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

HD Dong et al.

NATURE MEDICINE (2002)